Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2025
|
| In: |
ESMO open
Year: 2025, Jahrgang: 10, Heft: 5, Pages: 1 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2025.105062 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2025.105062 Verlag, kostenfrei, Volltext: https://www.esmoopen.com/article/S2059-7029(25)00931-7/fulltext 
|
| Verfasserangaben: | M. von Lilienfeld-Toal, S. Agkatsev, A. Glasmacher, P. Reiß, S. Sen, A. Seltmann & S. Wolf |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1941726933 | ||
| 003 | DE-627 | ||
| 005 | 20251120161854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251120s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2025.105062 |2 doi | |
| 035 | |a (DE-627)1941726933 | ||
| 035 | |a (DE-599)KXP1941726933 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lilienfeld-Toal, Marie von |d 1971- |e VerfasserIn |0 (DE-588)121251268 |0 (DE-627)081183585 |0 (DE-576)29260937X |4 aut | |
| 245 | 1 | 0 | |a Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |c M. von Lilienfeld-Toal, S. Agkatsev, A. Glasmacher, P. Reiß, S. Sen, A. Seltmann & S. Wolf |
| 264 | 1 | |c May 2025 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffenticht: 11. April 2025 | ||
| 500 | |a Gesehen am 20.11.2025 | ||
| 700 | 1 | |a Agkatsev, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glasmacher, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reiß, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sen, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seltmann, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolf, S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 10(2025), 5 vom: Mai, Artikel-ID 105062, Seite 1 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:5 |g month:05 |g elocationid:105062 |g pages:1 |a Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |
| 787 | 0 | 8 | |i Ergänzung zu |a Puhr, Hannah Christina, 1994 - |t Ethnic origin in cancer clinical trials |d 2025 |w (DE-627)1931738319 |
| 787 | 0 | 8 | |i Ergänzung |a Puhr, Hannah Christina, 1994 - |t Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |d 2025 |w (DE-627)1941608957 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2025.105062 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.esmoopen.com/article/S2059-7029(25)00931-7/fulltext |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251120 | ||
| 999 | |a KXP-PPN1941726933 |e 4809438937 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online veröffenticht: 11. April 2025","Gesehen am 20.11.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["European Society for Medical Oncology"]},"id":{"eki":["84705344X"],"zdb":["2844985-X"],"issn":["2059-7029"]},"origin":[{"dateIssuedDisp":"2016-","publisher":"Elsevier ; BMJ","dateIssuedKey":"2016","publisherPlace":"[London] ; London"}],"language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology","role":"isb"}],"recId":"84705344X","disp":"Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022ESMO open","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 13.06.24"],"part":{"text":"10(2025), 5 vom: Mai, Artikel-ID 105062, Seite 1","volume":"10","year":"2025","pages":"1","issue":"5"},"pubHistory":["1.2016 -"],"title":[{"title_sort":"ESMO open","title":"ESMO open","subtitle":"cancer horizons"}]}],"language":["eng"],"recId":"1941726933","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"May 2025"}],"title":[{"title":"Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022","title_sort":"Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022"}],"id":{"doi":["10.1016/j.esmoop.2025.105062"],"eki":["1941726933"]},"person":[{"family":"Lilienfeld-Toal","given":"Marie von","display":"Lilienfeld-Toal, Marie von","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Agkatsev, S.","given":"S.","family":"Agkatsev"},{"given":"A.","family":"Glasmacher","role":"aut","roleDisplay":"VerfasserIn","display":"Glasmacher, A."},{"display":"Reiß, P.","roleDisplay":"VerfasserIn","role":"aut","family":"Reiß","given":"P."},{"given":"S.","family":"Sen","role":"aut","roleDisplay":"VerfasserIn","display":"Sen, S."},{"given":"A.","family":"Seltmann","role":"aut","display":"Seltmann, A.","roleDisplay":"VerfasserIn"},{"given":"S.","family":"Wolf","role":"aut","display":"Wolf, S.","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["M. von Lilienfeld-Toal, S. Agkatsev, A. Glasmacher, P. Reiß, S. Sen, A. Seltmann & S. Wolf"]}} | ||
| SRT | |a LILIENFELDLETTERREET2025 | ||